Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$75 Mln
P/E Ratio
--
P/B Ratio
0.81
Industry P/E
--
Debt to Equity
0.15
ROE
-0.96 %
ROCE
-86.04 %
Div. Yield
0 %
Book Value
1.09
EPS
-1.31
CFO
$-326.85 Mln
EBITDA
$-373.66 Mln
Net Profit
$-381.49 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Tenaya Therapeutics Inc (TNYA)
| -68.53 | -35.61 | -67.63 | -89.91 | -65.99 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Tenaya Therapeutics Inc (TNYA)
| -55.57 | 61.19 | -89.39 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein... C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Address: 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 Read more
CEO, Secretary & Director
Mr. Faraz Ali M.B.A.
CEO, Secretary & Director
Mr. Faraz Ali M.B.A.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Tenaya Therapeutics Inc (TNYA) stood at $ 120 Mln as on 31-Dec-24
The share price of Tenaya Therapeutics Inc (TNYA) is $0.45 (NASDAQ) as of 17-Apr-2025 16:21 EDT. Tenaya Therapeutics Inc (TNYA) has given a return of -65.99% in the last 3 years.
Tenaya Therapeutics Inc (TNYA) has a market capitalisation of $ 75 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Tenaya Therapeutics Inc (TNYA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Tenaya Therapeutics Inc (TNYA) and enter the required number of quantities and click on buy to purchase the shares of Tenaya Therapeutics Inc (TNYA).
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Address: 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
The CEO & director of Mr. Faraz Ali M.B.A.. is Tenaya Therapeutics Inc (TNYA), and CFO & Sr. VP is Mr. Faraz Ali M.B.A..
There is no promoter pledging in Tenaya Therapeutics Inc (TNYA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Tenaya Therapeutics Inc (TNYA) | Ratios |
|---|---|
|
Return on equity(%)
|
-95.69
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Tenaya Therapeutics Inc (TNYA) was $0 Mln.
$-0.01
(
